TY - JOUR
T1 - Executive summary
T2 - Japanese guidelines for atopic dermatitis (ADGL) 2021
AU - Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, The Japanese Society of Allergology, The Japanese Dermatology Association
AU - Saeki, Hidehisa
AU - Ohya, Yukihiro
AU - Furuta, Junichi
AU - Arakawa, Hirokazu
AU - Ichiyama, Susumu
AU - Katsunuma, Toshio
AU - Katoh, Norito
AU - Tanaka, Akio
AU - Tsunemi, Yuichiro
AU - Nakahara, Takeshi
AU - Nagao, Mizuho
AU - Narita, Masami
AU - Hide, Michihiro
AU - Fujisawa, Takao
AU - Futamura, Masaki
AU - Masuda, Koji
AU - Matsubara, Tomoyo
AU - Murota, Hiroyuki
AU - Yamamoto-Hanada, Kiwako
N1 - Funding Information:
According to the criteria for the conflict of interest (COI) at the institutions of each committee member or the “COI Management Guidelines” and the “Guidance on Eligibility for Participation in the Formulation of Clinical Practice Guidelines” of the Japanese Association of Medical Sciences, the committee members of the present guidelines disclosed their COIs for the past 3 years until the inauguration and each year until the publication of the guidelines. The costs to develop the guidelines have been supported by grants for research from the JDA and Japanese Society of Allergology (JSA). The members of this committee have not received any rewards for the development of the guidelines or participation in related meetings. There has been no intervention by the JDA or JSA that may influence the contents of the guidelines. To avoid any influence by potential COIs, if any, on the guidelines, all recommendations were determined based on consensus voting, rather than on individual opinion, with reference to the opinions of the representatives of the JDA and JSA (public comments).
Funding Information:
According to the criteria for the conflict of interest (COI) at the institutions of each committee member or the “COI Management Guidelines” and the “Guidance on Eligibility for Participation in the Formulation of Clinical Practice Guidelines” of the Japanese Association of Medical Sciences, the committee members of the present guidelines disclosed their COIs for the past 3 years until the inauguration and each year until the publication of the guidelines. The costs to develop the guidelines have been supported by grants for research from the JDA and Japanese Society of Allergology (JSA) . The members of this committee have not received any rewards for the development of the guidelines or participation in related meetings. There has been no intervention by the JDA or JSA that may influence the contents of the guidelines. To avoid any influence by potential COIs, if any, on the guidelines, all recommendations were determined based on consensus voting, rather than on individual opinion, with reference to the opinions of the representatives of the JDA and JSA (public comments).
Publisher Copyright:
© 2022 Japanese Society of Allergology
PY - 2022/10
Y1 - 2022/10
N2 - This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, the description about three new drugs, namely, dupilumab, delgocitinib, and baricitinib, has been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
AB - This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, the description about three new drugs, namely, dupilumab, delgocitinib, and baricitinib, has been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85138582680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138582680&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2022.06.009
DO - 10.1016/j.alit.2022.06.009
M3 - Review article
C2 - 36064654
AN - SCOPUS:85138582680
VL - 71
SP - 448
EP - 458
JO - Allergology International
JF - Allergology International
SN - 1323-8930
IS - 4
ER -